about
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also ge...
Read More
225.04
5.97
(2.73%)
432.9K
XNAS Volume
XNAS 22 Sep, 2026 1:57 PM (EDT)
Low Financial Strength
Mid Valuation
Technically Neutral
Await Turnaround
These stocks have poor financials and average valuation and momentum. Investors should be cautious about these stocks
View Similar
Embed DVM
Biogen Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..